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Highlights 
 Ruthenium(III) complexes were successfully synthesised. 
 The substitution of the coordinated chloro ligands happened simultaneously. 
 Density functional theoretical calculations supports substitution kinetic results.  
 Complexes demonstrate low antineoplastic properties against Hela cancer cells. 
 Molecular docking  of the compounds demonstrate good affinity for DNA molecule. 
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Graphical abstract 
  
In all substitution kinetics reactions, a single step, considered to be the displacement of the 
coordinated chlorides was seen with no solvation pathway. Due to the symmetrical nature of 
the investigated ruthenium(III) complexes, the three chloride ligands are equally substituted 
simultaneously. The docking experiments reveal that the binding energies of the complexes 
have direct correlation to their kinetic stability. 
Keywords: ruthenium(III) complexes; substitution kinetics; density functional theory; 
molecular docking;  cytotoxicity;  anti-cancer activities 
 
Abstract  
The present work investigates the kinetics of ligand substitution reaction and anticancer 
activities of the complexes, [{2-(2-pyridyl) benzimidazole} RuCl3] (C1), [{2-(2-pyridyl) 
benzoxazole} RuCl3] (C2), [{2-(2-pyridyl) benzothiazole} RuCl3] (C3) and [{1-propyl-2- 
(pyridin-2-yl)-H-benzoimidazole} RuCl3] (C4). The substitution kinetics reaction of the 
complexes with the three bio-relevant nucleophiles, viz.: thiourea (TU), 1, 3-dimethyl-2-
thiourea (DMTU) and 1, 1, 3, 3-tetramethyl-2-thiourea (TMTU) was investigated under 
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pseudo first-order conditions as a function of concentration and temperature using UV-Visible 
spectrophotometer. The substitution of the coordinated chloride was controlled by the 
electronic effect. The order of reactivity of the complexes with the nucleophiles is in the form 
C1 > C2 > C3 > C4 which is in line with the density functional theory (DFT) studies. The 
complexes showed minimal anticancer activity against the HeLa cell line, which is in contrast 
to the molecular docking experiments that exhibited stronger DNA binding affinities. 
 
Introduction 
The documented clinical limitations of cisplatin and its second and third generation analogues 
have triggered the search for other anticancer agents containing metals other than platinum. 
Metals such as iridium, gold, cobalt, ruthenium and silver have so far shown good cytotoxicity 
[1-4]. These complexes appear to possess markedly lower toxicities, high tumour selectivity 
and enhanced solubility. Among the non-platinum metal compounds, ruthenium complexes 
seem to be the most promising class due to their structural and coordination properties.  These 
properties have been considered in a number of excellent reviews [5-8] and they include (i) 
accessibility to multiple oxidation states at physiological conditions, which makes them 
suitable for pharmaceutical use; (ii) octahedral geometry which differs from the square-planar 
molecular geometry of platinum(II) compounds, this allows for tuning of the steric and 
electronic properties of the complexes; (iii) a rate of ligand substitution kinetics that is close to 
those of cellular processes, giving the drug high kinetic stability and hence reducing side 
reactions; (iv) the ability of ruthenium metal to mimic iron in binding to serum transferrin and 
albumin proteins, which transports and solubilises iron in cytoplasm and thereby exploiting the 
body’s mechanism of nontoxic delivery of iron. 
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Over the years, most research groups have evaluated ruthenium complexes for their potential 
to inhibit the growth of tumours. The key focus has been on the interaction between active 
ruthenium compounds and their possible targets such as RNA and DNA [9-10]. It is widely 
accepted that the antineoplastic properties of ruthenium(II) and ruthenium(III) compounds is 
directly related to their ability to bind to DNA [11], although a few exceptions have been also 
reported [12]. Contributing to this field of study, Sadler [13-14] and Dayson [15-16] have 
developed structure-activity relationship using monofunctional compounds [Ru(η6- 
C6H6)(en)(Cl)]
+. The general mechanism for these half-sandwich ruthenium(II) arene 
complexes encompasses rapid loss of the choro ligand with the formation of more reactive aqua 
species, followed by the substitution kinetics of the labile aqua ligand by DNA and RNA. 
 
In the recent years, Bugarčić and his co-workers [17-21] have examined the anticancer 
activities of a series mononuclear ruthenium(II) chlorophenyl terpyridine complexes and 
establishing their  rate of substitution kinetics using L-histidine (L-His) and guanine derivatives 
(i.e., 9-methylguanine (9MeG) and 5′-GMP). They found that the rates of substitution kinetics 
of these complexes strongly depend on the nature of the inert chelating ligand on their inductive 
effect and the steric hindrance including the charge of the entering nucleophile. 
 
Two ruthenium(III) complexes, KP1019 and NAMI-A, are presently among the most 
successful drug candidates to enter human clinical trials [22-23]. The preliminary 
investigations of the two ruthenium compounds demonstrate that they might be promising in 
the treatment of drug-resistant tumours, as they are effective against cancerous cell lines that 
are highly resistant to other anticancer agents such as cisplatin and doxorubicin.  Despite, the 
success of these two ruthenium compounds, their mode of mechanism remains a matter of 
debate. The in vitro cytotoxic properties of a series of ruthenium(III) complexes with 
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dithiocarbamato ligands towards a panel of human tumour cell lines have been investigated 
[24-26]. The biological assays of most of these complexes on human tumour cell lines point 
out intriguing selectivity and antiproliferative properties. 
 
Building on the existing knowledge we have investigated the reactivity of mononuclear 
ruthenium(III) complexes by varying the identity of the heteroatoms on the inert ligand 
architecture. We have also examined their antineoplastic properties. Hence in this contribution 
we report the substitution kinetics and anticancer activities of ruthenium(III) complexes 
supported by 2-(2-pyridyl)benzoazole ligands with   thiourea nucleophiles viz; TU, DMTU, 
TMTU. Thiourea nucleophiles act as good model compounds for thioether and thiolate which 
are present in the cytoplasm. The binding of metal complexes with S-containing biomolecules 
is accountable for the occurrence of toxic effects. The structures of the complexes and 
nucleophiles used in this study are shown in Scheme 1 and 2, respectively. The experimental 
work is supported by computational density functional theory (DFT) studies. 
 
Scheme 1: Structures of the investigated mononuclear (pyridyl)benzoazole ruthenium(III) 
complexes. 
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Scheme 2: Structures of the examined thiourea nucleophiles and its derivatives 
 
Experimental 
Chemicals 
All synthetic procedures were carried out under a nitrogen atmosphere using standard Schlenk 
techniques. Ruthenium(III) chloride hydrate (RuCl3.xH2O, 99.98%) was purchased from 
Merck and used as supplied. Methanol was obtained from Merck and distilled over magnesium 
prior to use.  Sodium perchlorate monohydrate (NaClO4.H2O, 98%), lithium chloride (LiCl, 
99%), thiourea (TU, 99%), N,N-dimethyl-2-thiourea (DMTU, 99%), N,N,N,N-tetramethyl-2-
thiourea (TMTU, 98%) were all obtained from Sigma-Aldrich and used as supplied. 
 
Characterisations and instrumentations 
Thermal Scientific Flash 2000 and a Carlo Erba Elemental Analyzer 1106. Mass spectrometry 
measurements were recorded on an LC Premier micro-mass spectrometer. Kinetic experiments 
were performed on Varian Cary 100 Bio UV-Visible spectrophotometer with an attached 
Varian Peltier temperature-controller and an online kinetic applications and the temperature of 
the instrument was controlled within ± 0.1 °C. 
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Preparation of (pyridyl)benzoazole ligands 
The following ligands, namely, 2-(2-pyridyl)benzimidazole (L1), 2-(2-pyridyl)bezoxazole 
(L2), 2-(2-pyridyl)bezothiazole (L3) and 1-propyl-2-(pyridin-2-yl)-1H-benzo[d]imidazole 
(L4) were synthesised for this investigation. The ligands, L1-L3 were all synthesised using a 
method previously described in literature [27]. For the preparation of L4, this method was 
slightly modified as described by Ogweno et al [28]. 
 
Synthesis of (pyridyl)benzoazole ruthenium(III) complexes 
Synthesis of [{2-(2-pyridyl) benzimidazole}RuCl3] (C1)  
Complex C1 was synthesised according to our published literature procedure [28]. A mixture 
of ligand L1 (0.09 g, 0.48 mmol) and RuCl3.3H2O (0.10 g, 0.48 mmol) was refluxed in absolute 
ethanol (20 mL) for 4 h. A brown precipitate was collected by filtration, washed thoroughly 
with excess ethanol and dried to obtain complex C1 as a brown solid. Yield = 0.08 g (38%). 
TOF MS-ES, m/z (%) 402.07, (M+ + H). Anal. Calcd (%) for C12H9Cl3N3Ru: C, 35.80; H, 2.25; 
N, 10.44. Found (%): C, 35.98; H, 2.19; N, 10.66. 
 
Synthesis of [{2-(2-pyridyl)benzoxazole}RuCl3] (C2)  
Complex C2 was prepared following the synthetic procedure for C1, using ligand L2 (0.21 g, 
0.98 mmol) and RuCl3·3H2O (0.20 g, 0.98 mmol) to afford a brown solid. Yield = 0.395 g 
(31%). TOF MS-ES, m/z (%) 404.12, (M+ + H). Calcd (%) for C12H8Cl3N2ORu: C, 35.71; H, 
2.00; N, 6.94; O, 3.96. Found (%): C, 35.41; H, 1.78; N, 7.03; O, 4.06. 
 
Synthesis of [{2-(2-pyridyl)benzothiazole}RuCl3] (C3) 
The procedure used in the synthesis of complex C1 was used in the preparation of C3, using 
ligand L3 (0.21 g, 0.98 mmol) and RuCl3·3H2O (0.20 g, 0.98 mmol) to yield a light brown 
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solid. Yield = 0.411g (76%). TOF MS-ES, m/z (%) 420.09 (M+ + H). Calcd (%) for 
C12H8Cl3N2RuS: C, 34.34; H, 1.92; N, 6.67; S, 7.64. Found (%): C, 34.63; H, 1.02; N, 6.92; S, 
7.47. 
 
Synthesis of [{1-propyl-2-(pyridin-2-yl)-H-benzoimidazole}RuCl3] (C4)  
This complex was synthesised following the synthetic procedure described for complex C1, 
using ligand L4 (0.21 g, 0.98 mmol) and RuCl3·3H2O (0.20 g, 0.98 mmol) to produce complex 
C4 as a brown solid. Yield = 0.09 g (43%). TOF MS-ES, m/z (%) 408, (M+ + -Cl).  Calcd (%) 
for C15H15Cl3N3Ru: C, 40.51; H, 3.40; N, 9.45. Found (%): C, 40.09; H, 3.08; N, 9.64. 
 
Preparation of nucleophile solutions for kinetic measurements 
The stock solutions of nucleophiles, viz. thiourea (TU), 1,3-dimethyl-2-thiourea (DMTU) and 
1,1,3,3-tetramethyl-2-thiourea (TMTU) were prepared shortly before use by dissolving known 
amounts of the nucleophiles in 0.1 M (adjusted with NaClO4 and LiCl) methanol solutions to 
afford a concentration of approximately 150 times greater than that of the metal complex. The 
other nucleophile solutions were prepared by subsequent dilutions of the same stock solutions 
to obtain a series of standards of 120, 90, 60 and 30 times the concentration of the metal 
complex. The NaClO4 was used because perchlorate ions do not bind to the ruthenium(III) 
metal centre. In addition, LiCl was added to prevent possibility of any spontaneous solvolytic 
reactions.  
 
Kinetic procedure 
The rate of substitution of the coordinated chloride from each of the four compounds of 
ruthenium(III) was investigated using a series of neutral sulphur-donor nucleophiles viz. TU, 
DMTU and TMTU using UV-Vis spectrophotometer. All kinetic investigations were 
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conducted under pseudo-first order conditions, in which the concentration of the incoming 
nucleophile was at least 30-fold excess of the complexes so as to force the substitution reactions 
to completion [29]. The working wavelengths were pre-determined by recording spectra of the 
reaction mixture over the wavelength range 200–850 nm to establish suitable wavelengths at 
which their kinetic measurements could be investigated.   
 
Computational modelling 
Computational modelling was performed by the Gaussian09 program package to gain a clear 
understanding of the electronic and structural differences of the investigated compounds [30]. 
The geometry optimisations, frequency calculations, and mapped molecular orbital diagrams 
were carried out at density functional theoretical (DFT) level based on B3LYP/LanL2DZ (Los 
Alamos National Laboratory 2 double ξ) level theory [31-32]. The singlet state was adopted 
due to the low electronic spin of (pyridyl)benzoazoles ruthenium(III) compounds. The 
compounds were computed with methanol solvent, considering the solvolysis effects by means 
of the Conductor Polarizable Continuum Model [33-34]. 
 
Cytotoxicity assay  
The human cervical carcinoma HeLa cells were used for the cytotoxicity experiments as 
previously reported [35]. They were grown in 75 cm2 tissue culture flasks using Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% Foetal Calf Serum, 2 mM L-
glutamine, 1% non-essential amino acid and 1% antibiotic-antimycotic solution. They were 
incubated at 37 oC in a humidified atmosphere of 5% CO2. At about 80-90% confluency, the 
medium was removed and cultures were rinsed with pre-warmed PBS, trypsinised and seeded 
into micro-clear, flat-bottom 96-well plates at a density of 5 x 104 cells per ml (100 µl/well). 
After 24 h, a range of  concentrations up to 400 µM was prepared from the DMSO stock 
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concentration of each tested compound  and added to the cultures, each in triplicate (the final 
highest concentration (v/v) of DMSO in the growth medium that the cultures were exposed to 
was confirmed not to affect cell viability), and plates were incubated for 48 h, after which 
viability was assessed using the 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide [MTT] assay [36]. This was done by adding to each well 10 µl of the MTT solution 
(5 mg/ml, prepared in sterile PBS) before incubating the plates for 3 h. Thereafter the content 
of each well was aspirated and 100 µl of DMSO was added to dissolve the insoluble formazan. 
The absorbance of each well was then read at a wavelength of 570 nm using the CLARIOstar 
plate reader (BMG Labtech). Changes to the morphology of the cells caused by the treatments 
were monitored on an Olympus CKX41 microscope fitted with an Olympus DP71 U-TVIX-2 
camera. Images were captured using the Olympus cellSens entry software. 
 
For each treatment the mean of the triplicate values was calculated. The mean of the control 
cultures (cultures not exposed to treatment with any compound) was then set to 100% and the 
mean viability for each concentration normalised to it. Values are represented as Mean ± SEM 
(standard error of the mean). Statistical analyses were done using GraphPad (Version 7.03, 
GraphPad Software, Inc., CA, USA). Statistically significant differences between the means 
were determined using analysis of variance (ANOVA) followed by a post-hoc test for multiple 
comparisons (Tukey test). A P-value of less than 0.05 was considered statistically significant. 
IC50 for each compound was determined using GraphPad by fitting the data to the non-linear 
regression of log [inhibitor] versus response (3 parameters or 4 parameters (variable slope)). 
 
Molecular docking experiment 
Molecular docking studies were performed using HEX 8.0.0 software, which uses spherical 
polar Fourier correlations to accelerate the calculations. All calculations were carried out on an 
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Intel Core i3-4170 CPU using the following parameters; correlation type: (shape + electro); 
search order: 25; receptor/ligand: 180; step sizes: 7.5; grid dimension: 0.6; number of solutions: 
2000. The structures of the compounds were sketched by CHEMSKETCH [37] and converted 
to PDB format from MOL format using Mercury software [38]. The crystal structure of the B-
DNA dodecamer d(CGCGAATTCGCG)2 (PDB ID: 1BNA) was downloaded from the protein 
data bank [39]. All water molecules were removed before docking calculations with the 
examined compounds. The docked poses were visualised using UCSF Chimera software [40]. 
 
Results  
Kinetic analyses 
All substitution kinetics experiments showed that all reactions were characterised by a single 
step that could be studied using UV-Visible spectroscopy. A typical Spectral changes and 
kinetic trace obtained by monitoring the reaction between TU and C3 as shown in Figure 1.  
 
 
Figure 1: Spectral changes and kinetic trace obtained from the UV-Visible spectrometer with 
a single exponential fit for the reaction between C3 (5.0 x 10-4 mol dm-3) and TU (1.5 x 10-2 
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mol dm-3) in methanol followed at 310 nm, I = 0.1 M (0.01 M LiCl, 0.09 M NaClO4), T = 298 
K. 
All the kinetic traces for the substitution reactions provided excellent fits to first-order 
exponential decay to produce, pseudo-first-order rate constants, kobs, at specific concentrations 
of the nucleophiles and temperature. The kobs, were established by a nonlinear least square fit 
of the absorbance-time data to Equation 3.1 using Origin 7.5® software graphical analysis 
software [41]. 
At = Ao + (Ao - A∞) e
 (-k
obs.
)t                                                                                                    (1) 
where Ao, At and A∞ represent absorbance of the mixture of the reaction at the start of the 
reaction at time, t  and at the end of the reaction, respectively. The dependence of the rate 
constant on the concentration of the incoming nucleophiles was analysed for all the examined 
nucleophiles while keeping the temperature at 25 °C. The kobs was calculated as a mean of at 
least three independent kinetic experiments. The second-order rate constant, k2, for the reactions 
of the ruthenium(III) complexes with the incoming nucleophiles were attained from the slopes 
of the graphs of kobs versus the concentration of the incoming nucleophile using Origin 7.5® 
software. Representative plots for complex C1 are shown in Figure 2. In all cases, the reactions 
displayed a first-order dependence on the concentration of the incoming nucleophile.  
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Figure 2: Concentration dependence of kobs for the substitution of chlorides from C1 (1.0 x 10
-
4 M) by thiourea nucleophiles in methanol solution, I = 0.1M (0.01 M LiCl, 0.09 M NaClO4) 
at 298 K. 
The plots gave straight line fits with zero intercept for each of the investigated nucleophiles. 
Therefore, the proposed mechanism of substitution is as shown in Scheme 3 and the 
corresponding rate law is represented by Equation 1, showing that the kinetic pathway is 
irreversible and does not depend on the solvent. The values of the second-order rate constant 
k2, which were obtained from the slopes of these plots at 25 °C are summarised in Table 1.  
 
Scheme 3: Proposed substitution mechanism for the ruthenium complexes supported by 2-(2-
pyridyl)benzoazole ligands 
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kobs = k2 [nucleophile]                                                               (1) 
Table 1: Summary of the rate constants and activation parameters for the substitution of 
chloride by TU, DMTU and TMTU in methanol solution, I = 0.1 M (0.01 M LiCl, 0.09 M 
NaClO4) at 298 K 
 
Complex Nu k2/M-1s-1 ΔH≠/kJmol-1 ΔS≠/Jmol-1K-1 
 
 
C1 
TU (2.47 ± 0.02) ×10-2 65 ± 1 -43 ± 3 
 
DMTU 
 
(1.67 ± 0.03) ×10-2 
 
76 ± 1 
 
-11 ± 4 
 
TMTU 
 
(9.7 ± 0.05) ×10-3 
 
78 ± 1 
 
-20 ± 3 
 
 
C2 
TU (1.33 ± 0.04) ×10-2 68 ± 1 -48 ± 3 
 
DMTU 
 
(9.0 ± 0.02) ×10-4 
 
83 ± 2 
 
-25 ± 5 
 
TMTU 
 
(7.0 ± 0.03) ×10-4 
 
84 ± 1 
 
-24 ± 3 
 
 
C3 
TU (4.6 ± 0.02) ×10-3 64 ± 1 -60 ± 3 
 
DMTU 
 
(5.0 ± 0.02) ×10-4 
 
84 ± 2 
 
-27 ± 6 
 
TMTU 
 
(2.0 ± 0.01) ×10-4 
 
85 ± 1 
 
-37 ± 4 
 
 
C4 
TU (2.0 ± 0.01) ×10-3 69 ± 1 -74 ± 3 
 
DMTU 
 
(4.0 ± 0.01) ×10-4 
 
88 ± 1 
 
-13 ± 3 
 
TMTU 
 
(1.0 ± 0.01) ×10-4 
 
90 ± 1 
 
-19 ± 3 
 
The second order rate constant k2, was also determined as a function of temperature, over a 
temperature range of 25-45 °C at intervals of 5 °C to obtain the activation parameters for 
substitution of the coordinated chlorides from ruthenium(III) complexes. The enthalpy of 
activation (ΔH≠) and entropy of activation (ΔS≠), were calculated using Eyring equation [42]. 
The values of ΔS≠ and ΔH≠ were calculated from the intercepts and slopes of Eyring plots, 
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respectively. These parameters are tabulated in Table 1. Representative Eyring plots obtained 
for the reactions of C1 with the three nucleophiles are shown in Figure 3.  
0.00310 0.00315 0.00320 0.00325 0.00330 0.00335 0.00340
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2
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Figure 3: Eyring plot obtained for the substitution of chloride from C1, by thiourea 
nucleophiles I = 0.1 M (0.01 M LiCl, 0.09 M NaClO4) in methanol at various temperatures in 
the range 25 - 45 °C. 
 
Computational calculations 
Computational analyses of the ruthenium(III) complexes were determined in order to help 
explain the kinetic trends observed and the influence of the molecular structures as well as the 
electronic properties of the complexes on the observed reactivity. Table 2 shows an extract of 
the geometry optimised structures, LUMO and HOMO frontier molecular orbitals for the 
complexes while Table 3 shows a summary of the corresponding properties of the frontier 
molecular orbitals: HOMO-LUMO, NBO atomic charges and bond lengths.  
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Table 2: DFT frontier molecular orbitals and minimum energy structures of ruthenium(III) 
complexes C1-C4  as established by density functional theory using B3LYP level of theory 
and LANL2DZ basis set 
Geometry-optimised 
structure  
     HOMO map    LUMO map        Planarity 
C1 
 
 
 
 
C2 
    
C3 
 
   
C4 
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Table 3: Summary of the data obtained from the DFT calculations for the ruthenium(III) 
complexes 
 
 
 
 
   C1 
 
   C2 
 
  C3 
 
  C4 
LUMO /eV -3.67 -3.82 -3.80 -2.90 
HOMO /eV -6.79 -6.96 -6.97 -6.74 
ΔE /eV 3.12  3.14  3.16  3.83 
Chemical hardness (η) 3.12 3.14 3.16 3.83 
Electronic chemical potential (μ) -5.23 -5.39 -5.39 -4.82 
Electrophilicity index (ω) 4.38 4.63 4.60 3.03 
NBO Charges     
Ru  0.354  0.348 0.344 0.316 
X -0.394 -0.251 0.358 -0.170 
N1 -0.382 -0.347 -0.313 -0.310 
Bond Length ( Å)     
Ru-Cl bond length a 2.43 2.42 2.40 2.38 
Ru-N1 2.06 2.07 2.11 2.30 
NBO = natural bond orbital, aaverage Ru-Cl bond length of three chlorides. 
 
 In vitro cytotoxicity testing to assess potential anti-cancer activity  
All the complexes were screened for their in vitro cytotoxicity against the HeLa cell, with 
doxorubicin used as a standard reference. The effects of doxorubicin (up to 20 µM) and the 
complexes (each up to 400 µM) on cell viability were determined after cells were exposed to 
them for 48 h. Doxorubicin decreased HeLa cell viability in a concentration-dependent manner, 
with an IC50 of 0.8 ± 0.2 µM, while the complexes did not cause significant reductions in cell 
viability at the concentrations tested, except that C2 at 400 µM reduced viability to 82.6 ± 0.3% 
(P<0.05) (Table 4). 
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Table 4: In vitro cytotoxic activity results (IC50 µM) of ligands and complexes against Hela 
cella  
Compound IC50 (in µM) 
Doxorubicinb    0.8 
C1   >200 
C2   >200 
C3   >200 
C4   >200 
aIC50 values obtained by MTT assay results after 48 h drug exposure at various concentrations.  
Results are presented as mean ± SD of three independent experiments. bReference drug. 
 
Molecular docking analyses 
The investigated compounds were docked within the DNA duplex of sequence 
d(CGCGAATTCGCG)2 dodecamer (PDB ID: 1 BNA) to determine the binding site inside the 
DNA. Docked images and relative binding energies of the ruthenium(III) complexes are 
summarised in Table 4. 
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Table 5: Molecular docking results of ruthenium(III) complexes 
Complex       Docked images of complexes Relative binding 
energy of complexes 
(kJ/Mol) 
 
 
 
C1 
 
      
 
 
 
-216.57 
 
 
 
C2 
 
     
 
 
-220.63 
 
 
 
C3 
 
    
 
 
-226.14 
 
 
C4 
 
    
 
 
-244.03 
 
Discussion  
Comparing the rates of displacement of the coordinated chloride from the ruthenium(III) 
complexes, a clear general trend is observed from the reactivity data in Table 1. Using the rate 
constant of C1 with TU as a reference point, the ratio of the rate of substitution of the chloro 
from the complexes is 10:5:2: 1 for C1: C2: C3: C4, respectively. Therefore, the reactivity for 
the substitution of the chloride ligands by the thiourea nucleophiles decreases in the order of 
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C1 > C2 > C3 > C4. A similar order of reactivity trend was observed for all the investigated 
nucleophiles. The difference in reactivity is ascribed to the electronic effects of the heteroatoms 
of benzoazole of the ligand architecture.  
 
The identity of the heteroatom NH (C1); O (C2); S (C3); and N-propyl (C4) on the inert ligand 
framework affects the rate of substitution of the coordinated chlorides from ruthenium(III) 
complexes. The electronegativity of the heteroatoms aids in the withdrawal of electron density 
from the ligand, enhancing π-back bonding and thereby creating a more electrophilic metal 
centre [43]. Thus increasing the rate of the substitution kinetic reaction.  Evidence of π-back 
bonding is shown by the magnitude of the negative charge on the nitrogen atom attached to the 
ruthenium(III) metal centre. There is an increase of the negative NBO charge of the N1 with 
increase in electronegativity of the heteroatom, which is in the order NH > O > S > N-propyl. 
DFT data in Table 3 show that the NBO charges of N1 decrease from C1-C4. The back donation 
of electron density towards the ligand from the metal centre due to the influence of the 
electronegativity of the heteroatom on the inert ligand shortens the Ru-N1 bond length, thereby 
lengthening the Ru-Cl bond and thus enhancing reactivity as shown by the trend in the bond 
lengths (Table 3). 
 
Higher rate of displacement of coordinated chloride in C2 (O-atom) in comparison to C3 (S-
atom) is because oxygen is more electronegative than sulphur [44]. The DFT data show that 
the negative NBO charges of the heteroatoms decrease from C1-C3, leading to a decrease in 
the removal of electrons from the metal centre, making it more electrophilic and hence 
decreasing the rate of substitution reaction. This observation is in line with the observed second 
order rate constant, k2, values. The high rate of substitution of the chlorides observed for C1 
(N-H) is associated with the presence of the acidic amine proton which is electron deficient 
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and hence withdraws electrons from the nitrogen atom enhancing its electron withdrawal 
ability; this then increases the π-back donation effect of the ligand, thereby increasing the 
electrophilicity of the metal centre and thus the reactivity.  
 
The rate of displacement of coordinated chlorides in C4 (N-propyl) by the nucleophiles 
decreased by a factor of about 10 compared to C1. Addition of the alkyl group (N-propyl in 
C4), which is an electron donor, reduces electron withdrawing ability of the nitrogen atom and 
consequently lowering π-back donation. This argument is supported by the DFT data that show 
that the positive NBO charges of the ruthenium(III) metal centre decrease from C1-C4. The 
DFT data shows that the N1-Ru bond length follows the order C1 < C2 < C3 < C4, which is 
opposite to the Ru-Cl bond lengths that follow the order, C1 > C3 > C2 > C4. This observation 
affirms the argument that back donation of electron density from ruthenium(III) to the ligand 
shortens the N1-Ru bond and lengthens the Ru-Cl bond. 
 
DFT calculated frontier orbitals (Table 2) demonstrate that the electron density of the HOMO 
orbitals mostly lies on the ruthenium(III) metal centre and the chloride ligands while the 
LUMO electron density is largely located on the ligand framework, an indication of the 
influence from the metal centres due to their strong π-acceptor ability. This therefore creates a 
high electron density condition in both the occupied and unoccupied orbitals, and thus the 
ΔE(gap) decreases with the increase in the electronegativity of the atoms on the framework of 
the ligand. The observed comparable ΔE /eV of 3.12, 3.14, 3.16 and 3.83 for C1, C2, C3 and 
C4, respectively. 
 
In all of these studies a reverse reaction was not observed. Only a single step, considered to be 
the substitution of the coordinated chlorides was observed with no solvation pathway. Due to 
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the symmetrical nature of the mononuclear ruthenium(III) complexes, the three chloride 
ligands are equally susceptible to substitution which happens simultaneously. Comparing the 
rates of substitution by nucleophiles, TU, DMTU and TMTU these followed their steric 
hindrance ability with TMTU being the most sterically hindered nucleophile hence being the 
least reactive [45-46]. The observed relatively low ΔH‡ and negative ΔS‡ values is in line with 
the associative mode of activated process [47-48]. The negative ΔS‡ values signifies a decrease 
in disorder due to the bond formation in the transition state [49-50]. 
 
A preliminary investigation of complexes C1-C4 as potential anticancer drugs was carried out 
in vitro using HeLa cells (Table 4). The anti-cancer drug, doxorubicin, which was used as 
standard (reference drug), was potent in killing the cells, whereas the complexes had little 
cytotoxic effect. In anti-cancer drug discovery and design, inhibition of target biomolecules 
and selectivity of action are very essential. While current  results have not established a 
potential for the tested complexes as anti-cancer agents, our future studies will examine the 
effects of the complexes on a wider panel of cancer cells and on normal cells, in order to 
understand whether there exist any differential cytotoxic sensitivities to the complexes of a 
variety of cells representing different cancers, consistent with the heterogeneous nature of the 
pathology and also with a number of reports suggesting that HeLa cells could be resistant to 
(pyridyl)benzoazole ligands and their respective ruthenium(III) complexes [52-54]. The 
inactivity of the complexes C1-C4 could also be largely attributable to the low aromaticity 
(low number of the conjugated rings) of the (pridyl)benzoazole ligands, as found in a previous 
anti-cancer study of the ruthenium complexes [20], or to potential difficulty in their penetrating 
the cells to access and overwhelm target survival machineries to induce cell death.  Poor 
cytotoxicity of the complexes could also be due to their relatively lower rate of substitution 
kinetics [17-20]. 
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The docking experiments show the best possible intercalation between DNA groove structure 
and metal complexes. The most stable docked poses suggest that all investigated complexes 
interact in a parallel manner with respect to the minor groove of the DNA backbone (Table 5). 
The molecular docking results reveal that the investigated ruthenium(III) complexes approach 
the DNA site forming stable complexes through non‐covalent interactions like hydrogen 
bonding and hydrophobic and van der Waals interactions. The relative binding energies of the 
complexes, summarised in Table 5, show the significant binding pattern of the complexes with 
the DNA [55]. The more negative the relative binding energy, the stronger the binding between 
DNA and complexes. Therefore, C4 has a stronger binding ability compared to other 
complexes, which may be due to its electronic property that favours the stacking interactions 
between DNA base pairs leading to hydrogen bonding and van der Waals and hydrophobic 
interactions. It was observed that the binding energies are directly proportional to the kinetic 
stability of the investigated complexes (the most kinetically stable complex having the lowest 
second-order rate constant, k2). 
Conclusion  
The study clearly demonstrated that the reactivity of ruthenium(III) complexes anchored on 
bidentate (pyridyl)benzoazole ligands can be systematically be tuned by varying the identity of 
the heteroatoms. The order of reactivity for the substitution of the chloride ligands by the 
thiourea ligands decreased in the order of C1 > C2 > C3 > C4 and this trend is due to electronic 
effect which iis linked to the electronegativity of the heteroatoms. This observation is supported 
by the DFT DATA. The displacement of the coordinated chlorides was also found to be 
sensitive towards the steric hindrance of the incoming nucleophiles. The observed ΔH‡ and ΔS‡ 
supported an associative mode of activation. The studied compounds exhibit poor cytotoxicity 
when compared to the reference compound, doxorubicin. The binding energies of the studied 
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complexes are inversely proportional to the rates of kinetic substitution. This study is of great 
importance for the development of new ruthenium anticancer drugs with reduced side effects.  
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